Enlivex Therapeutics (TASE:ENLV) - Hisse Senedi Fiyatı, Haberler ve Analizler

ENLV Stoklara Genel Bakış

Enlivex Therapeutics Ltd. iştirakleri ile birlikte İsrail'de klinik aşamada bir makrofaj yeniden programlama immünoterapi şirketi olarak faaliyet göstermektedir. Daha fazla detay

ENLV temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 22.7% oranında düşmesi öngörülüyor

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Hissedarlar geçen yıl sulandırıldı

+ 2 daha fazla risk

Enlivex Therapeutics Ltd. Rakipler

Grace Breeding

TASE:GRAC

₪66.7m

Clal Biotechnology Industries

TASE:CBI

₪59.0m

XTL Biopharmaceuticals

TASE:XTLB

₪80.3m

Can-Fite BioPharma

TASE:CANF

₪53.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Enlivex Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$3.89
52 Haftanın En Yüksek Seviyesi	US$16.00
52 Haftanın En Düşük Seviyesi	US$3.50
Beta	1.1
11 Aylık Değişim	-30.89%
3 Aylık Değişim	-16.80%
1 Yıllık Değişim	-43.60%
33 Yıllık Değişim	-82.60%
5 Yıllık Değişim	-86.37%
Halka arzdan bu yana değişim	-96.14%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	ENLV	IL Biotechs	IL Pazar
7D	-0.9%	-7.1%	2.6%
1Y	-43.6%	-12.3%	26.1%

Getiri vs. Endüstri: ENLV geçen yıl % -12.3 oranında getiri sağlayan IL Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: ENLV geçen yıl % 26.1 oranında getiri sağlayan IL Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ENLV's price volatile compared to industry and market?
ENLV volatility
ENLV Average Weekly Movement	7.8%
Biotechs Industry Average Movement	4.9%
Market Average Movement	4.1%
10% most volatile stocks in IL Market	7.3%
10% least volatile stocks in IL Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: ENLV hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ENLV 'nin haftalık oynaklığı son bir yılda 14% dan 8% a düştü, ancak hâlâ IL hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	n/a	Oren Hershkovitz	www.enlivex.com

Enlivex Therapeutics Ltd. iştirakleriyle birlikte İsrail'de klinik aşamada bir makrofaj yeniden programlama immünoterapi şirketi olarak faaliyet göstermektedir. Ürün hattı, sepsisin neden olduğu organ disfonksiyonunun tedavisi için faz II klinik çalışmasında olan Allocetra'dır. Şirket ayrıca, orta dereceli diz osteoartriti ve son evre diz osteoartriti tedavisi için faz I/II klinik çalışmasında olan Allocetra'yı geliştirmektedir.

Enlivex Therapeutics Ltd. Temel Bilgiler Özeti

Enlivex Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ENLV temel i̇stati̇sti̇kler
Piyasa değeri	₪83.69m
Kazançlar(TTM)	-₪81.46m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-1.0x

F/K Oranı

ENLV aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ENLV gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$22.29m
Kazançlar	-US$22.29m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.04
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

ENLV uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ENLV Stoklara Genel Bakış

Risk Analizi

Enlivex Therapeutics Ltd. Rakipler

TASE:GRAC

₪66.7m

TASE:CBI

₪59.0m

TASE:XTLB

₪80.3m

TASE:CANF

₪53.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Recent updates

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Receives Authorization from the Danish Medicines Agency to Initiate the Phase Ii Stage of Its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation to Initiate the Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 31, 2024

New major risk - Revenue and earnings growth

Enlivex Therapeutics Ltd. Receives Regulatory Authorization for the Initiation of A Phase I Clinical Trial to Evaluate Allocetra in Patients with Psoriatic Arthritis

Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis

High number of new and inexperienced directors

Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis

New minor risk - Shareholder dilution

Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ in Patients with Sepsis

New major risk - Revenue and earnings growth

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 02, 2023

Enlivex Therapeutics Ltd. (NasdaqCM:ENLV) announces an Equity Buyback for $1.5 million worth of its shares.

Enlivex Therapeutics Ltd., Annual General Meeting, Oct 26, 2023

Enlivex Therapeutics Ltd. Announces Addition to the Ongoing Phase II Trial of Allocetra in Patients with Sepsis, Initiates Clinical Program in Osteoarthritis

Enlivex Therapeutics Ltd. Announces Publication of Clinical and Exploratory Data from A Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 United States

Enlivex Therapeutics Ltd Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

New major risk - Financial position

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (Crs) Resulting from Car T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Enlivex Therapeutics Ltd. Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Authorizations from French and Belgian Regulatory Agencies to Expand Its Phase II Sepsis Clinical Trial into France and Belgium

Enlivex Receives Allocetra Ind Clearance from the U.S. Food and Drug Administration for Treatment of Patients with Advanced Solid Malignancies

Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd., Annual General Meeting, Nov 17, 2022

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra to Prevent Cytokine Release Syndrome in Patients Receiving CAR T Cell Therapy

Enlivex Therapeutics Ltd. Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex Therapeutics Ltd. Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra

Sheba Medical Center and Enlivex Therapeutics Ltd. Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Receives Israeli Ministry of Health Authorization for the Initiation of Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Announces New Preclinical Data in Ovarian Cancer Showing Substantial Survival Benefit When Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology Annual Meeting

Enlivex Therapeutics Ltd. Awarded Its Third Non-Dilutive Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis Patients

Enlivex Therapeutics Ltd. Announces Appointment of Roger J. Pomerantz to its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Appoints Roger J. Pomerantz to Its Board of Directors as Vice Chairman

Enlivex Therapeutics Ltd. Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting

Insufficient new directors

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand Its Phase IIb Trial Evaluating Allocetra in Severe and Critical Covid-19 Patients into Greece

Enlivex Therapeutics Ltd. Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece

Enlivex Doses First Patient in Placebo-Controlled Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients with ARDS

Enlivex Therapeutics Ltd.: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant

Enlivex Awards Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

Enlivex Therapeutics Ltd Receives Notice of Allowance for Japanese Patent Application

Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy

Enlivex Therapeutics Ltd. Announces Issuance of U.S. Patent No. 10,927,343 Covering AllocetraTM, the Immunotherapy Product Candidate

Enlivex Therapeutics Ltd. Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update

New 90-day high: ₪43.50

Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on Medrxiv

Enlivex Therapeutics Ltd Reports Positive Interim Results of an Investigator-Initiated Phase Ii Clinical Trial Evaluating Allocetratm in Severe and Critical Covid-19 Patients

Enlivex Therapeutics Ltd. Reports Positive Two-Year Clinical Outcome for Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra

Enlivex Appoints Dr. Brian Schwartz to the Board of Directors